APTObenzinga

Aptose Receives Fast Track Designation For HM43239 In Relapsed/Refractory AML Patients And FLT3 Mutation

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on May 4, 2022 by benzinga

Aptose Receives Fast Track Designation For HM43239 In Relapsed/Refractory AML Patients And FLT3 Mutation | APTO Stock News | Candlesense